Newsroom | 39062 results

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company’s common stock at an exercise price per share of $28.72, which was the...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2026, and provided a business update. “We continue to execute against our strategy of building a diversified targeted oncology company with multiple opportunities to bring needed therapies to patients,” said Clay B. Siegall, Ph.D., President and Chief Executive Of...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the second quarter ended June 30, 2026. “AN2 will have three Phase 2 programs underway by the end of this year, all of which have the potential to address major unmet needs. Our near-term focus is advancing start-up activi...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Claritas Rx, the patient journey experts, announced today it has been named to the 2026 Inc. 5000 list for the second consecutive year, earning a place among America's fastest-growing private companies. The list is the most prestigious ranking of the nation’s most successful independent and entrepreneurial businesses, recognizing companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the eco...

MEMPHIS, Tenn.--(BUSINESS WIRE)--When the 2026 FedEx St. Jude Championship tees off August 12-16 at TPC Southwind, art created by patients at St. Jude Children’s Research Hospital® will once again bring stories of hope, resilience and healing to one of golf’s biggest stages. The world’s top 70 PGA TOUR pros, along with fans and a global audience, will see St. Jude patient art throughout the week on caddie bibs during tournament play, TaylorMade® headcovers and PING golf bags. For children facin...

SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis Inc., the global leader in enterprise digital validation and compliance solutions, announced that a specialized Indian pharmaceutical joint venture focused on cytotoxic and oncology drug manufacturing, has selected the ValGenesis validation lifecycle management platform to modernize equipment qualification across its operations in India. The company manufactures injectable and sterile products for regulated global markets, operating state-of-the-...

TEL AVIV, Israel--(BUSINESS WIRE)--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced an ongoing translational research collaboration with Gilead Sciences supporting its global antibody-drug conjugate (ADC) clinical development programs. As oncology drug development increasingly depends on understanding tissue biology in its spatial context, AI-powered tissue analytics are b...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymph...

SAN FRANCISCO--(BUSINESS WIRE)--The Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) today announced the appointment of Brad Schneider, Ph.D., as Chief Operating Officer. Dr. Schneider brings more than two decades of experience in infectious disease research, global health operations, and AI biosecurity to his new role focused on advancing QBI's operational infrastructure and translating its science into real-world impact. "Brad brings something rar...